Table 2 Real world data PD-L1 positivity rate vs. clinical trial PD-L1 positivity rate.
PD-L1 IHC indication and cutoff | Positivity rate (real-world data) | Positivity rate (clinical trial data) | Clinical trial name |
|---|---|---|---|
NSCLC (TPS1-49) | 28.6% (4766/16,666) | 39.1% (646/1653) | KEYNOTE-024 |
34.2% (344/1007) | KEYNOTE-010 | ||
NSCLC (TPS 50) | 31.1% (5189/16,666) | 30.2% (500/1653) | KEYNOTE-024 |
22.8% (230/1007) | KEYNOTE-010 | ||
ESCC (CPS 10) | 59.8% (61/102) | 42.8% (157/367) | KEYNOTE-181 |
Urothelial carcinoma (CPS 10) | 46.5% (550/1183) | 30.5% (110/361) | KEYNOTE-052 |
HNSCC (CPS 1) | 95.2% (297/312) | 85% (754/882) | KEYNOTE-048 |
Cervix cancer (CPS 1) | 83.7% (431/515) | 83.7% (82/98) | KEYNOTE-158 |
GE adenocarcinoma (CPS 1) | 79.0% (1156/1463) | 58.0% (148/257) | KEYNOTE-059 |
Breast carcinoma (IC 1) | 39.3% (900/2289) | 40.1% (369/902) | IMPassion130 (TNBC patients only) |
